Cannabis wordt veel gebruikt als een zelf-medicatie van patiënten met een breed scala aan symptomen en ziekten, waaronder chronische niet-kanker pijn.
De veiligheid van het gebruik van cannabis voor medische doeleinden is niet systematisch onderzocht.
Voor meer zie onderstaand orgineel artikel van Jpain.Org
Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS)
Cannabis is widely used as a self-management strategy by patients with a wide range of symptoms and diseases including chronic noncancer pain.
The safety of cannabis use for medical purposes has not been systematically evaluated.
We conducted a prospective cohort study to describe safety issues among subjects with chronic noncancer pain. A standardized herbal cannabis product (12.5% THC) was dispensed to eligible subjects for a one-year period; controls were subjects with chronic pain from the same clinics who were not cannabis users. The primary outcome consisted of serious adverse events (SAEs) and non-serious adverse events (AEs). Secondary safety outcomes included pulmonary and neurocognitive function and standard hematology, biochemistry, renal, liver and endocrine function. Secondary efficacy parameters included pain and other symptoms, mood, and quality of life.
Two hundred and fifteen individuals with chronic pain were recruited to the cannabis group (141 current users and 58 ex-users) and 216 controls (chronic pain but no current cannabis use) from seven clinics across Canada. The median daily cannabis dose was 2.5g/d. There was no difference in risk of SAEs (adjusted IRR=1.08, 95% CI=0.57-2.04) between groups. Medical cannabis users were at increased risk of non-serious AEs (adjusted IRR=1.73, 95% CI=1.41-2.13); most were mild to moderate. There were no differences in secondary safety assessments.
Quality-controlled herbal cannabis, when used by cannabis-experienced patients as part of a monitored treatment program over one year, appears to have a reasonable safety profile. Longer term monitoring for functional outcomes is needed.
The study was registered with www.controlled-trials.com (ISRCTN19449752).
This study evaluated the safety of cannabis use by patients with chronic pain over one year. The study found that there was a higher rate of adverse events among cannabis users compared to controls but not for serious adverse events at an average dose of 2.5g herbal cannabis per day.
Meer artikelen over pijn, vindt je hier